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Abstract  Chronic  Obstructive  Pulmonary  Disease  (COPD)  phenotypes  have  become  increasingly
recognized  as  important  for  grouping  patients  with  similar  presentation  and/or  behavior,  within
the heterogeneity  of  the  disease.  The  primary  aim  of  identifying  phenotypes  is  to  provide
patients with  the  best  health  care  possible,  tailoring  the  therapeutic  approach  to  each  patient.
However,  the  identiﬁcation  of  speciﬁc  phenotypes  has  been  hindered  by  several  factors  such
as which  speciﬁc  attributes  are  relevant,  which  discriminant  features  should  be  used  for  assign-
ing patients  to  speciﬁc  phenotypes,  and  how  relevant  are  they  to  the  therapeutic  approach,
prognostic  and  clinical  outcome.  Moreover,  the  deﬁnition  of  phenotype  is  still  not  consen-
sual. Comorbidities,  risk  factors,  modiﬁable  risk  factors  and  disease  severity,  although  not
phenotypes,  have  impact  across  all  COPD  phenotypes.
Although  there  are  some  identiﬁed  phenotypes  that  are  fairly  consensual,  many  others  have
been proposed,  but  currently  lack  validation.  The  on-going  debate  about  which  instruments
and tests  should  be  used  in  the  identiﬁcation  and  deﬁnition  of  phenotypes  has  contributed  to
this uncertainty.
In  this  paper,  the  authors  review  present  knowledge  regarding  COPD  phenotyping,  discuss
the role  of  phenotypes  and  comorbidities  on  the  severity  of  COPD,  propose  new  phenotypes∗ Corresponding author.
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and  suggest  a  phenotype-based  pharmacological  therapeutic  approach.  The  authors  conclude
that a  patient-tailored  treatment  approach,  which  takes  into  account  each  patient’s  speciﬁc
attributes  and  speciﬁcities,  should  be  pursued.
© 2016  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.U.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
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hronic  Obstructive  Pulmonary  Disease  (COPD)  is  a  com-
lex,  multicomponent,  heterogeneous  disease.  The  classical
OPD  classiﬁcation  has  been  based  on  Forced  Expiratory  Vol-
me  in  the  ﬁrst  second  (FEV1),  but  this  alone  is  no  longer
ccepted  as  a  single  parameter  to  deﬁne  severity  or  to
uide  treatment.1 The  updated  Global  Initiative  for  Chronic
bstructive  Lung  Disease  (GOLD)  recommendations  propose
reatment  approach  based  on  two  additional  parameters,
ymptoms  and  exacerbations,  which  may  still  be  insufﬁcient
o  reﬂect  the  heterogeneity  of  COPD.  There  is  a  real  need  to
dentify  speciﬁc  attributes  in  order  to  group  the  heteroge-
eous  COPD  population  into  different  phenotypes,  and  guide
 patient  oriented  therapeutic  approach.  Several  pheno-
ypes  have  already  been  proposed,2--21 but  the  understanding
f  which  attributes  deﬁne  which  groups  of  patients  remains
 challenge.
It is  recognized  that  future  studies  should  focus  on  estab-
ishing  simple  algorithms  based  on  the  most  discriminant
eatures  for  assigning  patients  to  speciﬁc  phenotypes.  Such
lgorithms  have  to  be  tested  in  validation  cohorts  before
hey  can  be  used  in  clinical  practice.4 Han  et  al.  propose  a
chema  to  identify  candidate  phenotypes  and  validate  them
nce  their  relevance  to  clinical  outcomes  is  established.6
COPD  patients  frequently  have  several
omorbidities6,14,15,18,22,23 that  should  be  actively  sought
or  and  duly  addressed  therapeutically.  Some  associations
etween  comorbidities  and  phenotypes  have  been  identi-
ed,  and  although  they  are  relevant  to  the  overall  severity
nd  risk,  their  real  impact  on  COPD  is  not  clearly  established.
In  this  paper,  the  authors  review  present  knowledge  and
ccepted  criteria  for  these  crucial  aspects  of  the  disease,
ropose  deﬁnitions  for  phenotyping  COPD,  discuss  the  role  of
henotypes  and  comorbidities  on  the  severity  of  COPD,  and
uggest  a  therapeutic  approach  for  consensual  phenotypes.
henotypes, risk factors and severity
henotypes
ith  the  recognition  that  FEV1 is  not  sufﬁcient  to  character-
ze  and  classify  COPD  patients,  the  concept  of  phenotypes
e-emerged,  and  the  traditional  concept  of  ‘‘blue  bloaters’’
nd  ‘‘pink  puffers’’,  abandoned  in  the  past,  is  now  being
eplaced  by  a  variety  of  different  phenotypes.24 The  phen-
typing  process  emerges  as  a  consequence  of  the  clinical
eed  to  group  patients  with  similar  presentation  and/or
ehavior,  within  the  heterogeneity  of  the  disease,  in  order
o  provide  them  with  the  best  health  care  possible,  tailo-
ing  the  therapeutic  approach  to  each  patient  in  terms  of
f
(
iymptoms  control,  disease  progression,  health  status  and
uality  of  life.
Han  et  al.6 proposed  the  following  phenotype  deﬁnition:
‘a  single  or  combination  of  disease  attributes  that  describe
ifferences  between  individuals  with  COPD  as  they  relate  to
linically  meaningful  outcomes  (symptoms,  exacerbations,
esponse  to  therapy,  rate  of  disease  progression,  or  death)’’.
t  follows  from  this  deﬁnition  that  patients  may  be  classiﬁed
nto  distinct  prognostic  and  therapeutic  subgroups.  Mirav-
tlles  et  al.25 simplify  this  deﬁnition  by  saying  that  ‘‘the  term
OPD  phenotype  is  reserved  for  the  different  clinical  types
hat  have  therapeutic  impact  and  are  identiﬁed  in  COPD
atients’’.  Salzman  proposes  that  an  outcome  can  also  be
ncluded,24 and  some  authors  suggest  that,  depending  on  the
ontext,  some  COPD  features,  e.g.,  dyspnea  or  exacerba-
ions,  could  be  considered  both  outcomes  and  phenotypes.26
We  propose  that  a  phenotype  is  an  attribute  or  a  set  of
ttributes  that  can  be  clinically  characterized,  is  somewhat
table  over  time,  and  deﬁne  a  relevant  group  of  individuals,
oth  in  terms  of  therapeutic  and  prognostic  implications.
isk  factors
he  latest  GOLD  guidelines  contemplate  the  cross-
ombination  of  two  distinct  dimensions:  a symptom
imension,  assessed  by  the  Modiﬁed  Medical  Research  Coun-
il  Dyspnea  Scale  (mMRC)  or  the  COPD  Assessment  Test
CAT),  and  a risk  dimension,  assessed  by  FEV1 and  frequency
f  exacerbations.  Patients  are  classiﬁed  as  A,  B,  C,  or  D
epending  on  the  combination  of  these  three  parameters.25
owever,  different  patients  exist  within  the  risk  dimension,
iven  that  a  risk  assessment  based  on  the  degree  of  airﬂow
bstruction  is  different  from  a  risk  assessment  based  on  the
ccurrence  of  exacerbations.  Moreover,  exacerbations  have
ifferent  types,  severity  and  presentations,  and  are  not  pre-
ictive  of  the  same  risk.  Also,  patients  may  have  symptoms
nd  risk  that  are  independent  of  the  respiratory  disease,
amely  the  presence  of  signiﬁcant  comorbidities.
Thus,  risk  and  symptoms  should  be  considered  vectors
r  dimensions  of  COPD,  which  can  be  present  in  several
henotypes.
Some  factors  can  be  present  in  several  phenotypes
nd  modify  the  development  and  clinical  course  of  COPD.
n  this  view,  comorbidities  would  be  modifying  factors
ince  they  both  change  over  time  and  can  exist  across
ll  phenotypes,27 and  so  would  inﬂammation28 and  genetic
olymorphisms,11,29 since  they  modify  the  expression  of  rec-
gnized  phenotypes.  However,  no  precise  deﬁnition  exists
or  modifying  factors  in  COPD.
In COPD,  the  most  consensual  modiﬁable  risk  factor
or  behavior)  is  smoking.  Other  modiﬁable  behaviors  that
mpact  COPD  are  Body  Mass  Index  (BMI)30 and  physical
ties  
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activity.31 Environmental  exposure  such  as  exposure  to  air
pollution  can  be  modiﬁable  but  can  hardly  be  considered  a
behavior.  Furthermore,  it  can  be  argued  that  professional
exposure  is  considered  a  modiﬁable  risk  factor,  as  for  some
patients  it  contributes  to  worsening  of  the  disease  and  it  can
be  interrupted.
Severity
Historically,  assessment  of  COPD  severity  was  based  solely
on  FEV1.  Currently,  and  although  spirometry  is  required
to  establish  a  diagnosis  of  COPD,  it  is  considered  insuf-
ﬁcient  to  describe  COPD  severity.1,15,32 A  comprehensive
assessment  of  COPD  including  symptom  assessment  using
validated  questionnaires  such  as  mMRC,  the  Clinical  COPD
Questionnaire  (CCQ)33 and  CAT,34 degree  of  airﬂow  limi-
tation,  risk  of  exacerbations,  existence  of  comorbidities,1
overall  impact  of  COPD  in  a  patient’s  Quality  of  Life  (QoL),
and  exercise  tolerance35 and  levels  of  physical  activity,
is  now  recommended.  The  latter  is  particularly  important
because  the  amount  of  physical  activity  a  patient  takes
and  their  functional  status  predict  exacerbations,  hospi-
talizations,  and  mortality.31 Indeed,  the  UPLIFT  study  has
shown  that  although  FEV1 did  not  differ  between  treat-
ment  groups  (long-acting  muscarinic  antagonist  [LAMA]  vs
placebo),  health  status,  time  to  ﬁrst  exacerbation  and  time
to  exacerbation  resulting  in  hospital  admission  were  bet-
ter  in  the  LAMA  group,36 strongly  suggesting  that  FEV1
per  se  is  not  sufﬁcient  to  determine  disease  severity.  The
TORCH  study  showed  that  FEV1 declined  faster  in  current
smokers,  patients  with  a  lower  body  mass  index,  patients
with  moderate  disease,  and  patients  who  exacerbated  more
frequently,37 also  suggesting  that  comorbidities  might  be
major  determinants  of  disease  severity.18
COPD  severity  is  different  from  COPD  activity.  Severity
has  been  proposed  as  a  concept  that  should  be  related  to
loss  of  organ  function  that  eventually  impacts  on  functional
impairment  and  prognosis,  whereas  COPD  activity  relates  to
the  activation  level  of  the  cellular  mechanisms  underlying
disease  progression.26
We  propose  that  disease  severity  should  be  deﬁned  by
mortality  risk,  daily  impact  of  the  disease  and  loss  of  organ
function.
Identifying phenotypes in COPD
Detailed  questionnaire  data  and  pulmonary  function
tests  have  been  proposed  to  differentiate  between  COPD
phenotypes.12 Multidimensional  indexes  built  to  strat-
ify  risk/severity  are  not  useful  in  identifying  different
phenotypes.  Nevertheless,  functional  measurements  of
severity  that  correlate  with  mortality  in  COPD,  such  as
FEV1,  the  ratio  of  inspiratory  capacity  to  total  lung  capacity
(IC/TLC),  the  diffusing  capacity  of  the  lung  for  carbon
monoxide  (DLCO),  6-min  walking  distance,  and  maximum
O2 consumption  or  maximum  watts  on  exercise  testing,
may  help  in  identifying  phenotypes.  Although  it  is  not
diagnostic,  bronchodilator  responsiveness  can  be  useful
in  the  distinction  between  asthma  and  COPD,  and  in  the
deﬁnition  of  the  mixed  asthma-COPD  (ACOS)  phenotype.
However,  pulmonary  function  tests  do  not  identify  subsets
that  respond  to  particular  therapies.24
p
H
i
a103
Imaging  techniques,  such  as  Computed  Tomogra-
hy  (CT),6,12,38--42 high-resolution  computed  tomography
HRCT)16,43 and  magnetic  resonance  imaging  (MRI)39 have
een  suggested  to  be  of  clinical  use  in  discriminating
etween  some  COPD  phenotypes,  and  may  be  novel  tools
hat  will  allow  for  a  more  accurate  diagnosis  and  help  guide
linical  management.39,40 The  usefulness  of  these  tech-
iques  is  still  debatable,  since  it  is  recognized  that  there
re  factors  not  easily  assessed  by  current  techniques.41
We  propose  that  a  combination  of  questionnaires,
bjective  parameters  such  as  pulmonary  function  tests,
ncluding  IC/TLC,  6-min  walking  distance,  exercise  testing
nd  thoracic  CT,  should  be  able  to  discriminate  between
henotypes.
ost  clinically  relevant  phenotypes
he  most  consensual  or  most  clinically  relevant  pheno-
ypes  are  the  non-exacerbator  phenotype,14 the  ACOS
henotype,8,12,14,15,17 the  exacerbator  with  emphy-
ema  phenotype,8,12,14,16 the  exacerbator  with  chronic
ronchitis,8,12,14,16,18 and  the  frequent  exacerbator.2,6,7,23
owever,  even  these  most  consensual  phenotypes  may
ot  be  easy  to  manage,  since  considerable  overlap  has
een  described  between  COPD  phenotypes  with  chronic
ronchitis,  emphysema  or  asthma,  which  has  therapeutic
onsequences.12 A  COPD-bronchiectasis  clinical  phenotype20
as  also  been  suggested.  The  Spanish  guidelines  recognize
he  need  to  identify  bronchiectasis  and  chronic  bronchial
nfection  in  patients  with  the  exacerbator  phenotype  with
hronic  bronchitis,  but  do  not  support  them  as  clinical
henotypes  with  their  own  clinical  relevance  for  the  time
eing.14
We  agree  with  the  less  symptomatic  non-exacerbator,
he  exacerbator  with  emphysema,  the  exacerbator  with
hronic  bronchitis,  and  ACOS  phenotypes  as  being  four  of
he  most  clinically  relevant  phenotypes,  propose  the  addi-
ion  of  the  symptomatic  non-exacerbator  with  emphysema
s  a  clinically  relevant  phenotype,  and  further  propose  that
he  COPD-bronchiectasis  should  be  considered  an  important
linical  phenotype  with  its  own  clinical  relevance  --  Fig.  1.
ther  potential  phenotypes
everal  other  COPD  phenotypes  have  been
roposed,3--5,10,11,13,21 but  it  remains  unclear  if  these
re  actually  speciﬁc  phenotypes.  The  proposed  fast
ecliner  phenotype19 can  only  be  identiﬁed  over  time
nd  not  a  priori  and  thus  it  is  difﬁcult  to  include  as  a
linical  phenotype.  The  combined  pulmonary  ﬁbrosis  and
mphysema  syndrome9 is  another  potential,  albeit  not
onsensual,  phenotype,  in  which  imaging  is  pivotal.  Since
any  aspects  of  COPD  clinical  phenotypes  are  related  to
nﬂammation,28 it  has  been  proposed  that  the  presence
f  systemic  inﬂammation  may  represent  a  unique  COPD
henotype,6 and  patients  with  substantial  systemic  inﬂam-
ation  and  relevant  comorbidities  might  form  speciﬁc
henotypes  that  lead  to  modiﬁed  treatment  strategies.18
owever,  this  is  not  consensual.27 Therefore,  systemic
nﬂammation  and  comorbidities  would  be  modifying  factors
nd  not  phenotypes.  Current  smokers  could  also  represent
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Chronic respiratory symptoms in patients with risk factors for COPD 
FEV 1/FVC post-BD <70% →  COPD
History of exacerbations
≥2/year
(or≥1 hospitalization)
<2/year
(no hospitalizations)
Wheezing as a dominant feature
Symptom variabilty
Significnt response to
bronchodilation
Sputum or peripheral
eosinophilia
Past history of bronchial asthma
Overlap asthma-COPD
(mixed phenotype)
Scarce symptoms
Severe lung overinflation
(IC/TLC<25%)
End-stage lung disease: Chronic respiratory failure
Heavily symptomatic
(marked exercise
intolerance)
Optional: Thoracic
CT showing
thickened
bronchial walls,
large / small-
airways mucoid
impaction
Cough and
phlegm most
of the days for
3 consecutive
months during
2 years
Thoracic CT:
Emphysema-
predominant
pattern
Thoracic CT:
Significant
bronchiectasis
Relatively preserved lung
function
Other features
Non exacerbatorExacerbator
Exacerbator with
emphysema Less symptomatic
Comorbidities
Symptomatic
(usually emphysematous)
COPD-
bronchiectasis
Exacerbator with
chronic bronchitis
Phenotype?
Clinical features, complete pulmonary function test (PFT) , thoracic CT scan, additional assessments
(sputum cytology, complete blodd count)
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oFigure  1  Proposed  most  
 different  phenotype,  but  since  they  must  be  identiﬁed
cross  all  phenotypes  and  intensive  smoking  cessation
trategies  must  be  adopted  in  these  individuals,27 smoking
ould  be  a  modiﬁable  risk  factor,  or  behavior,  and  not  a
henotype.  COPD  severity  is  not  a  phenotypic  feature  since
t  can  be  a  consequence  of  a  speciﬁc  clinical  phenotype.26
ndoubtedly,  the  issue  of  which  clinical  phenotypes  actually
xist  warrants  further  discussion.
Finally,  it  must  be  emphasized  that  comorbidities,  respi-
atory  failure  and  end-stage  disease  have  impact  across  all
OPD  phenotypes.
isk factors -- signiﬁcant comorbiditieshe  presence  of  signiﬁcant  comorbidities  is  perhaps  one
f  the  most  important  modifying  risk  factors  for  sever-
ty  in  COPD.  They  contribute  to  the  overall  severity  in
ndividual  patients,18,44 have  a  major  impact  on  quality
t
l
pally  relevant  phenotypes.
f  life,23 increase  the  risk  of  certain  causes  of  mortality
nd  of  all-cause  mortality3,15,23 and  are  major  causes  of
ospitalization,14,23 especially  cardiovascular  disease  (CVD)
nd  cancer.3,15,45 They  should  always  be  considered  as  a
ery  important  feature  in  all  patients,  regardless  of  the
tage  or  grade.
Although  the  prevalence  of  different  comorbidities  varies
ith  the  GOLD  stage,46 available  evidence  does  not  support
 relationship  between  comorbidities  and  GOLD  groups.  Dys-
nea,  health  status,  exacerbations  and  comorbidities  such
s  chronic  heart  failure  and  depression  are  markedly  dif-
erent  among  subjects  with  the  same  GOLD  classiﬁcation,
nderscoring  the  need  for  a  multidimensional  assessment
f  COPD  patients.3 Metabolic  and  cardiovascular  comorbidi-
ies  appear  relatively  unrelated  to  the  degree  of  airﬂow
imitation.4
Comorbidities  can  be  associated  with  any  clinical
henotype27 and  should  be  considered  in  a  comprehensive
ties  
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therapeutic  approach.  A  few  recent  studies  have  investi-
gated  associations  between  comorbidities  and  speciﬁc  COPD
phenotypes,47--50 or  identiﬁed  novel  phenotypes  associated
with  comorbidities,3--5,21 but  results  are  still  scarce  to  estab-
lish  associations  or  draw  deﬁnite  conclusions.  The  existence
of  COPD  is  associated  with  higher  risk  for  other  diseases,
such  as  cardiovascular  disease  and  lung  cancer,  but  whether
this  association  is  due  to  common  risk  factors  or  common
disease  pathways  (e.g.,  smoking),  susceptibility  genes,  or
impaired  clearance  of  carcinogens  is  not  clear.18,23 Given  the
fact  that  more  than  50%  of  COPD  patients  have  four  or  more
comorbidities,51 it  is  currently  difﬁcult  to  ascertain  whether
COPD  is  a  disease  distinct  from  its  comorbidities  or  whether
these  are  part  of  the  spectrum  of  COPD  manifestations.
Comorbidities  in  COPD  should  be  managed  in  the  same
way  as  for  all  other  patients  without  COPD.1 In  fact,  there
is  growing  evidence  that  some  of  the  treatments  used  for
comorbidities,  such  as  beta  blockers,  may  have  a  beneﬁcial
effect  on  the  course  of  COPD.  The  Spanish  guidelines
provide  an  outline  of  the  most  common  comorbidities  of
COPD,  with  its  diagnosis  and  treatment.14 Finally,  whether
treatment  of  co-morbid  conditions  alters  the  natural  history
of  COPD  or  whether  treatment  effectiveness  of  COPD  is
altered  by  the  presence  of  a  concomitant  comorbidity
awaits  further  study.6,52
Cardiovascular  disease
The  most  frequent  comorbidities  associated  with  COPD
are  those  related  to  the  cardiovascular  system.1,15,53,54
The  Lung  Health  Study  reported  that  cardiovascular  causes
accounted  for  42%  of  ﬁrst  hospitalizations  and  44%  of
second  hospitalizations  of  patients  with  relatively  mild
COPD,  whereas  respiratory  causes  accounted  for  only  14%
of  hospitalizations.15 Hypertension  seems  to  be  the  most
prevalent  cardiovascular  comorbidity1,53 across  all  GOLD
stages.46 COPD  patients  are  at  greater  risk  of  cardiovas-
cular  mortality,55 with  atrial  ﬁbrillation/ﬂutter,  congestive
heart  failure  and  coronary  artery  disease  having  a  combined
prevalence  of  58.9%  and  being  strongly  associated  with
increased  risk  of  death.53 Moreover,  heart  failure  prevalence
is  much  higher  among  patients  experiencing  an  exacerba-
tion,  and  is  the  leading  cause  of  hospitalization  and  death
in  COPD  patients.54 Also,  a  worsening  of  heart  failure  is  a
challenge  in  the  differential  diagnosis  of  an  exacerbation.1
The  presence  of  heart  failure  may  be  a  confounding  fac-
tor  as  well,  when  trying  to  identify  a  patient’s  phenotype.
With  respect  to  recurrent  interstitial  lung  edema,  it  may
be  responsible  for  wheezing  and  dyspnea  in  the  setting
of  chronic  obstructive  lung  disease,  thus  misidentifying  a
patient  as  having  ACOS.
It should  be  noted  that  different  cardiovascular  diseases
have  a  different  clinical  impact  on  COPD,  and  the  GOLD  2015
guidelines  propose  that  four  separate  entities  within  CVD
should  be  considered:  ischemic  heart  disease,  heart  failure,
atrial  ﬁbrillation  and  hypertension.1
Although  the  precise  mechanisms  by  which  COPD  may
be  a  risk  factor  for  CVD  are  not  fully  understood,  evi-
dence  has  suggested  that  airﬂow  limitation  and  particularly
hyperinﬂation  affect  cardiac  function  and  gas  exchange,
and  that  inﬂammatory  mediators  in  circulation  may  initi-
ate  or  worsen  comorbidities  such  as  ischemic  heart  disease
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nd  heart  failure.1,15 Hyperinﬂation  directly  affects  cardiac
imensions,  diastolic  ﬁlling,  systolic  ejection  fraction  and
ardiac  mass,  thus  being  a  crucial  component  for  some  of  the
ost  relevant  clinical  aspects  of  COPD,  dyspnea  and  exer-
ise  limitation.56,57 On  the  other  hand,  two  recent  reports
id  not  ﬁnd  differences  in  low-grade  systemic  inﬂammation
etween  ﬁve  identiﬁed  comorbidity  clusters,  one  of  which
as  cardiovascular,51 nor  conﬁrmed  that  a  more  inﬂamma-
ory  COPD  may  be  a  coronary  heart  disease  risk  factor.55 One
ossible  explanation  is  that  inﬂammation  is  indirectly  asso-
iated  with  cardiovascular  risk,  inﬂuencing  other  factors  or
omorbidities  that  in  turn  increase  the  cardiovascular  risk.
Cardiovascular  comorbidities  should  be  treated  according
o  usual  guidelines,  and  beta-blockers  should  not  be  with-
eld  from  these  patients,  although  selective  beta1-blockers
re  preferred.1 In  fact,  recent  studies  reported  a  reduc-
ion  of  the  risk  for  exacerbations  related  to  beta-blockers
se.  The  use  of  statins  to  reduce  exacerbations  is  more
ontroversial,  and  recent  studies  have  reported  different
esults.58--61
We  agree  that  COPD  patients  should  be  actively  treated
or  cardiovascular  comorbidities,  to  reduce  CV  exacerba-
ions  and  mortality  and  that  cardioselective  beta-blockers
hould  be  used  if  recommended  for  the  existing  cardiovas-
ular  comorbidity.
ung  cancer
 growing  body  of  evidence  supports  COPD  as  a risk  fac-
or  for  lung  cancer.62 However,  the  incidence  of  lung  cancer
mong  different  stages  of  COPD  has  shown  different  results,
ith  some  studies  ﬁnding  increased  incidence  with  COPD
everity45 and  others  reporting  the  opposite.63 A  possible
ustiﬁcation  for  these  contradictory  results  could  be  related
o  the  two  proposed  underlying  mechanisms  associating
OPD  to  lung  cancer:  if  a  patient  has  genetic  or  epigenetic
isk  factors  common  to  both  diseases,  then  lung  cancer  could
e  more  prevalent  at  less  severe  COPD  stages,  and  patients
n  the  more  severe  stages  would  not  have  the  predisposing
isk  factors;  if,  on  the  other  hand,  chronic  inﬂammation  is
he  culprit,  then  the  worse  the  COPD  severity,  the  higher
he  probability  of  developing  lung  cancer.  However,  the  true
eason  for  these  different  results  awaits  further  studies.
Early  lung  cancer  diagnosis  is  of  paramount  importance,
nd  a  recent  study  suggests  that  current  and  former  smok-
rs  with  COPD  may  beneﬁt  from  lower  pack-year  threshold
or  lung  screening  eligibility.64 A  potentially  interesting  com-
lementary  test  would  be  to  monitor  circulating  tumor  cells,
hich  have  been  shown  to  be  detected  in  patients  with  COPD
ithout  clinically  detectable  lung  cancer.65
Lung  cancer  in  COPD  patients  should  be  treated  according
o  lung  cancer  guidelines1.
We  propose  that  COPD  patients  should  be  screened  for
ung  cancer  regardless  of  their  smoking  history,  for  early
iagnosis.
utritional  anomalies,  anxiety/depression  and
etabolic pathologies
utritional  anomalies,  metabolic  disturbances  and  psycho-
ogical  disorders  are  three  comorbidity  clusters  identiﬁed
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n  COPD.51 The  link  between  COPD  and  these  and  other
requent  comorbidities  may  be  systemic  inﬂammation  due
o  spillover,66 but  this  hypothesis  remains  to  be  fully
roven.52,67 Depression  and/or  anxiety  are  common  in  COPD
nd  should  be  actively  sought  for,  due  to  their  associa-
ion  with  increased  risk  of  exacerbations  and  poorer  health
tatus.1 Lower  BMI  is  associated  with  a  higher  prevalence
f  acute  exacerbations46 and  is  an  independent  risk  factor
or  mortality  and  poor  prognosis.1 Patients  with  COPD  fre-
uently  have  one  or  several  components  of  the  metabolic
yndrome  and/or  type  2  diabetes,  and  several  mechanisms
ave  been  proposed  to  explain  the  link  between  COPD
nd  metabolic  disturbances.  However,  they  are  still  poorly
nderstood.68 Osteoporosis  is  also  a  very  frequent  comor-
idity  in  COPD,  often  not  diagnosed  especially  in  men,  and
ssociated  with  poor  health  status  and  prognosis.
Metabolic  and  psychological  comorbidities  should  be
reated  according  to  the  usual  guidelines,  with  special
ttention  to  BMI  in  patients  with  severe  COPD,  which  should
ot  fall  below  21  kg/m2.1
We  agree  that  these  comorbidities  should  be  actively
ought  for,  to  allow  early  treatment.  COPD  patients  will  ben-
ﬁt  from  a  multidisciplinary  treatment  approach,  including
utritional  counseling  and  psychologic  or  psychiatric  ther-
py.
ssessing severity in COPD
here  is  a  need  for  suitable  instruments  to  assess  disease
everity,  so  that  more  effective  therapeutic  measures  can
e  applied.  Studies  suggest  that,  although  COPD  patients
ith  more  severe  airﬂow  limitation  suffer  more  respiratory
ymptoms,  worse  quality  of  life  and  greater  comorbidities
han  those  with  milder  impairment,  lung  function  alone  does
ot  adequately  assess  the  impact  of  the  disease.35 Neverthe-
ess,  FEV1 has  to  be  measured  since  spirometry  is  essential
or  the  diagnosis  of  COPD,  to  evaluate  the  degree  of  airﬂow
imitation,1 to  monitor  disease  progression,  and  to  guide
herapy.69 A  low  FEV1 is  correlated  with  an  increased  risk
f  exacerbations1 and  poor  prognosis.69
As  for  the  assessment  of  other  parameters,  several  tools
nd  other  tests  are  currently  available,  such  as  ques-
ionnaires.  The  most  comprehensive  reliable  and  valid
isease-speciﬁc  health-related  quality  of  life  or  health
tatus  questionnaires1,34 are  the  St.  George’s  Respiratory
uestionnaire  (SGRQ)70 and  the  Chronic  Respiratory  Dis-
ase  Questionnaire  (CRQ).71 However,  they  are  both  lengthy
nd  have  scoring  algorithms  that  are  too  complex  to  use
n  routine  clinical  practice.1,34 CAT34 or  CCQ33 are  shorter,
ractical,  easy  to  use  measures  that  can  be  completed  in
wo  minutes,  and  are  considered  suitable  for  a  compre-
ensive  assessment  of  symptoms.1 Both  are  valid  to  assess
ealth  status  compared  to  the  extensive  SGRQ,  but  patients
refer  the  CCQ  since  it  reﬂects  their  status  better  than
AT,  as  it  has  more  details  on  breathing  problems.72 mMRC
ssesses  only  the  impact  of  dyspnea,  but  it  is  simple  to
se  and  recommended.1 The  information  provided  by  these
uestionnaires  may  be  too  scarce  to  accurately  score  COPD
everity,  but  all  questionnaires  have  limitations  and  cannot
xtensively  include  all  variables  relevant  to  assess  disease
everity.  All  these  scores  can  be  used  by  every  physician  that
•
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eals  with  COPD  patients.  One  report  advises  caution  when
lassifying  patients  according  to  the  GOLD  groups,44 since
he  classiﬁcation  obtained  by  the  mMRC  was  not  identical
o  the  one  obtained  using  CAT.73
Multicomponent  indexes  incorporate  several  dimensions
f  COPD.  The  three  most  commonly  used  multicomponent
ndices  are  BODE  (BMI,  FEV1,  dyspnea  and  6-min  walking
istance),30 BODEx  (BMI,  FEV1,  dyspnea  and  exacerbations)74
nd  ADO  (age,  dyspnea  and  FEV1),75 and  they  are  all  bet-
er  predictors  of  mortality  in  COPD  than  FEV1 alone.6 The
ODE  index  is  considered  to  be  the  reference  index,  the  best
alidated  and  of  wider  use.  However,  the  need  to  perform
he  6-minute  walking  test  renders  it  impractical  in  primary
are,  and  in  this  setting  it  can  be  replaced  by  the  BODEx
ndex.74 Both  indices  show  a  high  degree  of  correlation  and
 similar  prognostic  capacity  for  predicting  mortality.76 In
atients  with  more  severe  disease,  the  BODE  index  should
lways  be  used.14,76 BODE  seems  to  reﬂect  COPD  severity
etter  than  other  multidimensional  grading  systems,  but  not
ts  clinical  heterogeneity.77 The  ADO  index  seems  to  have
 better  medium-  and  long-term  predictive  reliability  when
ompared  to  other  indices,  but  after  adjusting  for  age,  BODE
nd  BODEx  have  a  better  prognostic  reliability.14 Moreover,
nd  although  ADO  seems  adequate  to  predict  survival  in
OPD  patients,75 it  needs  validations  across  a  wide  range  of
isease  severities.1 The  BODE  Index,  mBODE  (BODE  modiﬁed
n  grading  of  walked  distance),  e-BODE  (BODE  plus  exacer-
ations),  BODEx  and  the  ADO  index  are  all  better  predictors
f  mortality  in  COPD  than  FEV1 alone.
Other  indexes  such  as  the  COPD  Prognostic  index,  that
redicts  mortality,  hospitalization,  and  exacerbation  fre-
uency,  and  the  SAFE  and  DOSE  (Dyspnea,  Obstruction,
moking,  Exacerbation)  indexes,  which  also  predict  exacer-
ations,  may  be  useful6 as  well.  It  has  been  questioned
hether  prediction  of  mortality  rates  in  patients  using
ndexes  such  as  BODE  and  ADO  truly  indicates  patient-
erceived  severity  and  guides  appropriate  treatment,18 but
his  is  debatable  since  other  authors  argue  that,  being  mea-
urements  of  disease  severity,  they  are  useful  in  establishing
rognosis  and  guiding  therapy.78
All  the  above  mentioned  questionnaires  and  multi-
omponent  indexes  can  be  completed  during  physician
ppointments  and  are  therefore  subject  to  recall  bias.
nother  problem  inherent  to  the  use  of  questionnaires  is
he  potential  to  generate  amounts  of  data  that  are  not  pos-
ible  to  process  and  interpret  in  due  time,  thus  rendering
he  effort  useless.  A  balance  is  needed  between  the  use-
ulness  of  the  information,  the  time  it  takes  to  collect  and
rocess,  and  its  true  impact  on  therapeutic  choices.
There  are  currently  no  severity  scores  adapted  to  the
nown  clinical  phenotypes  that  can  be  used  to  guide  treat-
ent.  It  would  certainly  be  desirable  to  have  scores  that
etter  predict  severity  in  different  clinical  phenotypes,
nd  it  can  be  expected,  given  the  heterogeneity  of  COPD,
hat  multiple  variables  will  be  needed  for  different  COPD
ubtypes.19We  propose  the  combination  of  several  instru-
ents  to  assess  severity  in  COPD: FEV1 is  essential.
 mMRC  should  be  used  to  assess  the  impact  of  dyspnea  on
the  patient’s  daily  life.
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•  BODEx  can  be  used  in  a  primary  care  setting  but  BODE
must  be  used  for  more  advanced  disease,  in  a  respiratory
care  setting.
• Both  CAT  and  CCQ  are  better  in  deﬁning  symptoms,  but
CAT  has  the  added  advantage  of  assessing  disease  impact.
•  ADO  may  also  be  used  in  combination  with  the  above,  but
not  as  a  stand-alone  index.
Current  challenges  regarding  COPD  severity  and
the role  of  exacerbations
Several  aspects  of  COPD  severity  are  currently  being  chal-
lenged,  and  the  ﬁrst  is,  perhaps,  the  role  of  exacerbations
in  the  clinical  evolution  of  COPD.
An  exacerbation  can  be  deﬁned  as:
•  ‘‘an  event  that  leads  a  care  provider  to  prescribe
antibiotics  or  corticosteroids  (or  both)  or  that  leads  to
hospitalization  (severe  exacerbation)’’;7
•  ‘‘an  event  that  often  occurs,  where  there  is  a  rapid  and
sustained  worsening  of  symptoms  beyond  normal  day-to-
day  variations’’;32
•  ‘‘an  acute  event  characterized  by  a  worsening  of  the
patient’s  respiratory  symptoms  that  is  beyond  normal  day-
to-day  variations  and  leads  to  a  change  in  medication’’.1
Any  of  the  above  deﬁnitions  pose  challenges  for  use  in
clinical  phenotyping  and  severity  evaluation.  How  long  must
changes  in  symptoms  be  sustained  before  being  character-
ized  as  an  exacerbation,  is  it  two  to  three  days  or  less?
Moreover,  and  although  the  GOLD  deﬁnition  states:  ‘‘leads
to  a  change  in  medication,’’  the  criteria  invoked  by  health-
care  providers  to  judge  when  to  alter  medication  remains
unclear.  Are  these  changes  in  medication  quantitative  or
qualitative  or  both?  Importantly,  patient-recorded  increases
in  symptoms  that  appear  to  be  exacerbations  outnumber
those  that  cause  them  to  present  for  medical  attention.  In
addition,  events  with  worsening  symptoms  that  do  not  lead
patients  to  seek  additional  care  may  also  impact  prognosis.6
Which  clinical  or  biochemical  markers  can  or  should  be  used
to  identify  or  grade  severity  of  exacerbations?  These  are
unfortunately  unresolved  questions.
Nevertheless,  and  regardless  of  the  deﬁnition,  it  is  recog-
nized  that  exacerbations  contribute  to  the  overall  severity
in  individual  patients,  are  associated  with  an  increased
mortality,79 the  risk  of  exacerbations  increases  as  airﬂow
limitation  worsens,  and  hospitalization  for  a  COPD  exacer-
bation  is  associated  with  a  poorer  prognosis  and  increased
risk  of  death.1
Another  important  issue  is  that  assessment  of  disease
severity  as  envisaged  in  GOLD  does  not  seem  adequate.
The  GOLD  ABCD  classiﬁcation  results  in  very  heterogeneous
populations,80 and  does  not  reﬂect  disease  progression  or
mortality  risk,81,82 as  some  studies  have  shown  that  GOLD
B  patients  may  be  at  a  higher  mortality  risk  than  GOLD
C  patients.83 GOLD  anticipates  that  lung  function  can  be
expected  to  worsen  over  time,1 but  does  not  speciﬁcally
state  that  patients  may  switch  between  GOLD  categories,
although  an  analysis  from  the  ECLIPSE  study  reported  that
patients  may  indeed  switch  between  any  GOLD  categories.82
It  does  not  deﬁne  dyspnea  as  a  factor  for  worse  prognosis,
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ncludes  subsets  of  patients  deﬁned  by  low  lung  function
ith  patients  deﬁned  by  frequent  exacerbations,  and  does
ot  value  the  presence  of  respiratory  failure,  which  has
mportant  prognostic  and  therapeutic  implications.
The  non  inclusion  in  the  GOLD  report  of  respiratory  fail-
re  as  a  criterion  for  disease  severity1 can  have  impact  in
linical  practice.  Respiratory  failure  has  been  historically
onsidered  the  hallmark  of  end-stage  COPD,  and  thus,  is
ntrinsically  a  severity  criterion.  On  the  other  hand,  is  it
 severity  criterion  only  in  the  context  of  end-stage  dis-
ase,  or  should  respiratory  failure  be  a  severity  criterion
ndependent  of  end-stage  disease?
Finally,  a  patient  with  COPD  is  considered  to  be  well
ontrolled  who,  during  follow-up,  shows  minimal  or  no
ymptoms,  has  had  no  acute  exacerbations  since  the  last
ollow-up  visit,  and  no  impairment  in  QoL  while  receiving
he  current  treatment.76 Therefore,  in  the  same  manner
s  severity  assessment,  disease  control  should  be  multi-
omponent.  There  is  a  need  to  intervene  in  the  symptoms
nd  beyond  the  symptoms,  namely  using  pharmacological
nd  non-pharmacological  approaches  that  reduce  the  risk,
hich  means,  control  the  symptoms  and  control  the  disease
eyond  the  symptoms.
We  acknowledge  that  GOLD  is  useful  in  terms  of  gen-
ral  recommendations  and  public  health,  but  does  not  take
nto  account  the  several  phenotypes,  and  is  not  sufﬁcient  to
ssess  mortality  risk.
henotype-based therapeutic approach
nformation  regarding  speciﬁc  therapeutic  approaches
epending  on  the  phenotype  is  growing.  The  Canadian  guide-
ines  propose  treatment  based  on  frequent  or  infrequent
xacerbations15 and  GOLD  proposes  treatment  based  on
he  risk  and  symptoms.1 The  Spanish  guideline  proposes
reatment  of  COPD  based  on  four  clinical  phenotypes  and
isease  severity.14 Both  physiologic  measures  and  patient-
eported  outcome  questionnaires  will  help  identify  these
atient  phenotypes  and  allow  for  optimal  pharmacological
reatment  to  be  implemented.31
We  suggest  a  phenotype-based  pharmacological  ther-
peutic  approach,  considering  the  six  most  clinically
elevant  phenotypes  we  have  proposed  --  Table  1. The  non-
xacerbator  and  less  symptomatic  phenotype  may  start
ith  a  bronchodilator  that,  over  time,  will  preferably
e  a long-acting  medication.  In  the  strongly  symptomatic
on-exacerbator  with  emphysema  the  aim  should  be  max-
mum  bronchodilation.  The  exacerbator  phenotype  should
e  treated  ﬁrst  with  a  long-acting  bronchodilator  or  an
ssociation  of  bronchodilators,  to  control  symptoms.  If  not
ontrolled,  a  trial  of  inhaled  corticosteroid  (ICS)  association
s  recommended.  The  ACOS  phenotype  should  be  treated
ith  LABA/ICS  as  ﬁrst  option.  Whenever  an  ICS  is  recom-
ended,  the  risk  of  increased  bacterial  load84 should  be
aken  into  consideration.  Speciﬁc  ICS  drug  and  dose  should
lso  be  appropriately  chosen  since  there  is  no  evidence
hat  a  higher  dose  produces  better  results  and  the  available
olecules  are  not  equivalent.18,84 The  chronic  bronchitis
henotype,  if  not  controlled  with  the  proposed  previous
reatment,  can  be  treated  with  a  phosphodiesterase-4-
nhibitor  (PDE4i  --  currently  not  available  in  Portugal),
108  E.  Fragoso  et  al.
Table  1  Proposed  phenotype-based  pharmacological  therapeutic  approach.
Phenotype  Therapeutic  approach
Non-exacerbator  or  less  symptomatic SABA  or  SAMA
LABA  or  LAMA
Non-exacerbator,  symptomatic  with  emphysema  LABA  +  LAMA
LABA  +  LAMA  +  methylxanthines
Exacerbator  with  emphysema  LAMA  +  LABAa
LAMA  +  LABA  +  ICS
LAMA  +  LABA  +  ICS  +  methylxanthines
Exacerbator  with  chronic  bronchitis  LABA  +  ICS
LAMA  +  LABA  +  ICS  and/or  PDE4i
LAMA  +  PDE4i  +  cysteines
Mixed Asthma-COPD  (ACOS) LABA  +  ICS
LABA  +  ICS  +  LAMA
LABA  +  ICS  +  LAMA  +  methylxanthines
COPD-bronchiectasis  LABA  +  ICS
LABA  +  cysteines  +  long  term  macrolide
COPD -- Chronic Obstructive Pulmonary Disease; ACOS -- Asthma-COPD Overlap Syndrome; SABA -- short-acting beta agonist; SAMA -- short-
acting muscarinic antagonist; LABA -- long-acting 2-agonist; LAMA -- long-acting muscarinic antagonist; ICS -- inhaled corticosteroid;
PDE4i -- phosphodiesterase-4-inhibitor.
a Alternatively in case of a naïve patient, can initiate LAMA or LABA monotherapy, with a short-term follow-up, and in case of non-
m
s
a
l
a
d
m
c
t
p
a
r
e
c
c
r
n
w
a
E
P
d
a
C
d
R
d
C
T
f
t
m
i
R
F
F
r
r
t
p
A
T
i
s
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ucoactive  drugs  (acetylcysteine,  erdosteine)  and,  if  con-
idered  ineffective,  also  with  long-term  oral  antibiotics  (e.g.
zythromycin).  In  the  COPD-bronchiectasis  phenotype,  a
ong-term  oral  antibiotic  should  be  considered  and  inhaled
ntibiotics  could  also  be  useful  in  patients  with  end-stage
isease.
All  phenotypes  will  beneﬁt  from  non-pharmacological
easures  such  as  smoking  cessation,  inﬂuenza  and  pneumo-
occal  vaccination,  minimum  of  150  min/week  of  moderate
o  intense  physical  activity,  and  pulmonary  rehabilitation
rograms.
The  proposed  phenotype-based  pharmacological  ther-
peutic  approach  should  be  interpreted  as  a  general
ecommendation,  as  some  treatment  options  are  based  on
xpert  opinion.  We  recommend  patient  education,  including
orrect  inhalation  technique,  prompt  recognition  of  exa-
erbations,  and  adoption  of  healthy  lifestyles.  We  strongly
ecommend  that  treatment  should  be  patient-oriented  and
ot  COPD-oriented.  A  patient-tailored  treatment  approach,
hich  takes  into  account  each  patient’s  speciﬁc  attributes
nd  speciﬁcities,  should  be  pursued.
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